{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:53:05Z","timestamp":1793757185143,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS110703-01A1"],"award-info":[{"award-number":["1R01NS110703-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1U19CA264338-01"],"award-info":[{"award-number":["1U19CA264338-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA245969-01A1"],"award-info":[{"award-number":["1R01CA245969-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Given the marginal penetration of most drugs across the blood-brain barrier, the efficacy of various agents remains limited for glioblastoma (GBM). Here we employ low-intensity pulsed ultrasound (LIPU) and intravenously administered microbubbles (MB) to open the blood-brain barrier and increase the concentration of liposomal doxorubicin and PD-1 blocking antibodies (aPD-1). We report results on a cohort of 4 GBM patients and preclinical models treated with this approach. LIPU\/MB increases the concentration of doxorubicin by 2-fold and 3.9-fold in the human and murine brains two days after sonication, respectively. Similarly, LIPU\/MB-mediated blood-brain barrier disruption leads to a 6-fold and a 2-fold increase in aPD-1 concentrations in murine brains and peritumoral brain regions from GBM patients treated with pembrolizumab, respectively. Doxorubicin and aPD-1 delivered with LIPU\/MB upregulate major histocompatibility complex (MHC) class I and II in tumor cells. Increased brain concentrations of doxorubicin achieved by LIPU\/MB elicit IFN-\u03b3 and MHC class I expression in microglia and macrophages. Doxorubicin and aPD-1 delivered with LIPU\/MB results in the long-term survival of most glioma-bearing mice, which rely on myeloid cells and lymphocytes for their efficacy. Overall, this translational study supports the utility of LIPU\/MB to potentiate the antitumoral activities of doxorubicin and aPD-1 for GBM.<\/jats:p>","DOI":"10.1038\/s41467-024-48326-w","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T06:03:47Z","timestamp":1717653827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas"],"prefix":"10.1038","volume":"15","author":[{"given":"V\u00edctor A.","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Habashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1688-9663","authenticated-orcid":false,"given":"Crismita","family":"Dmello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo I.","family":"V\u00e1zquez-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Palac\u00edn-Aliana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0298-0191","authenticated-orcid":false,"given":"Graysen","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Amidei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristal","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silpol","family":"Dhiantravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Saganty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Cholak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McCord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-830X","authenticated-orcid":false,"given":"Kathleen","family":"McCortney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandyn","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Muzzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Desseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Canney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-7647","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-2810","authenticated-orcid":false,"given":"Jason M.","family":"Miska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-5107","authenticated-orcid":false,"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig M.","family":"Horbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas V.","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-3118","authenticated-orcid":false,"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-2124","authenticated-orcid":false,"given":"Catalina","family":"Lee-Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-1945","authenticated-orcid":false,"given":"Adam M.","family":"Sonabend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"48326_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks, W. A. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat. Rev. Drug Discov. 15, 275\u2013292 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"48326_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria, J. N. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20, 184\u2013191 (2018).","journal-title":"Neuro Oncol."},{"key":"48326_CR3","doi-asserted-by":"publisher","first-page":"e0169292","DOI":"10.1371\/journal.pone.0169292","volume":"12","author":"O Eidel","year":"2017","unstructured":"Eidel, O. et al. Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One 12, e0169292 (2017).","journal-title":"PLoS One"},{"key":"48326_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","volume":"27","author":"AA Brandes","year":"2009","unstructured":"Brandes, A. A. et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J. Clin. Oncol. 27, 1275\u20131279 (2009).","journal-title":"J. Clin. Oncol."},{"key":"48326_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-130","volume":"9","author":"BJ Gebhardt","year":"2014","unstructured":"Gebhardt, B. J. et al. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat. Oncol. 9, 130 (2014).","journal-title":"Radiat. Oncol."},{"key":"48326_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1158\/1078-0432.CCR-19-2182","volume":"26","author":"DY Zhang","year":"2020","unstructured":"Zhang, D. Y. et al. Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations. Clin. Cancer Res. 26, 477\u2013486 (2020).","journal-title":"Clin. Cancer Res."},{"key":"48326_CR7","doi-asserted-by":"publisher","unstructured":"Sabbagh A., et al. Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models. Clin Cancer Res. May;https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3760, (2021).","DOI":"10.1158\/1078-0432.CCR-20-3760"},{"key":"48326_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuroimage.2004.06.046","volume":"24","author":"K Hynynen","year":"2005","unstructured":"Hynynen, K., McDannold, N., Sheikov, N. A., Jolesz, F. A. & Vykhodtseva, N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24, 12\u201320 (2005).","journal-title":"Neuroimage"},{"key":"48326_CR9","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.ultrasmedbio.2005.07.010","volume":"31","author":"N McDannold","year":"2005","unstructured":"McDannold, N., Vykhodtseva, N., Raymond, S., Jolesz, F. A. & Hynynen, K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol. 31, 1527\u20131537 (2005).","journal-title":"Ultrasound Med Biol."},{"key":"48326_CR10","doi-asserted-by":"publisher","first-page":"eabj4011","DOI":"10.1126\/scitranslmed.abj4011","volume":"13","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Sci. Transl. Med. 13, eabj4011 (2021).","journal-title":"Sci. Transl. Med."},{"key":"48326_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04529-6","volume":"9","author":"N Lipsman","year":"2018","unstructured":"Lipsman, N. et al. Blood-brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound. Nat. Commun. 9, 2336 (2018).","journal-title":"Nat. Commun."},{"key":"48326_CR12","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-18-3643","volume":"25","author":"A Idbaih","year":"2019","unstructured":"Idbaih, A. et al. Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma. Clin. Cancer Res. 25, 3793\u20133801 (2019).","journal-title":"Clin. Cancer Res."},{"key":"48326_CR13","doi-asserted-by":"publisher","first-page":"343re2","DOI":"10.1126\/scitranslmed.aaf6086","volume":"8","author":"A Carpentier","year":"2016","unstructured":"Carpentier, A. et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med. 8, 343re2 (2016).","journal-title":"Sci. Transl. Med."},{"key":"48326_CR14","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-19-0932","volume":"25","author":"AM Sonabend","year":"2019","unstructured":"Sonabend, A. M. & Stupp, R. Overcoming the blood-brain barrier with an implantable ultrasound device. Clin. Cancer Res. 25, 3750\u20133752 (2019).","journal-title":"Clin. Cancer Res."},{"key":"48326_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yao.2023.01.017","volume":"3","author":"A Gould","year":"2023","unstructured":"Gould, A. et al. Advances in blood-brain barrier disruption to facilitate drug delivery for infiltrative gliomas. Adv. Oncol. 3, 77\u201386 (2023).","journal-title":"Adv. Oncol."},{"key":"48326_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45818-7","volume":"15","author":"A Carpentier","year":"2024","unstructured":"Carpentier, A. et al. Repeated blood\u2013brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial. Nat. Commun. 15, 1650 (2024).","journal-title":"Nat. Commun."},{"key":"48326_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend, A. M. et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24, 509\u2013522 (2023).","journal-title":"Lancet Oncol."},{"key":"48326_CR18","doi-asserted-by":"crossref","unstructured":"Ahmed, M. H. et al. Low-Intensity pulsed ultrasound-mediated blood-brain barrier opening increases anti-programmed death-ligand 1 delivery and efficacy in Gl261 mouse model. Pharmaceutics 15, 455 (2023).","DOI":"10.3390\/pharmaceutics15020455"},{"key":"48326_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMoa2308719","volume":"390","author":"AR Rezai","year":"2024","unstructured":"Rezai, A. R. et al. Ultrasound blood-brain barrier opening and aducanumab in Alzheimer\u2019s Disease. N. Engl. J. Med. 390, 55\u201362 (2024).","journal-title":"N. Engl. J. Med."},{"key":"48326_CR20","doi-asserted-by":"crossref","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","DOI":"10.1001\/jamaoncol.2020.1024"},{"key":"48326_CR21","doi-asserted-by":"publisher","unstructured":"Omuro A., et al. Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. Neuro Oncol. Apr 14;https:\/\/doi.org\/10.1093\/neuonc\/noac099, (2022).","DOI":"10.1093\/neuonc\/noac099"},{"key":"48326_CR22","doi-asserted-by":"publisher","unstructured":"Lim M., et al. Phase 3 trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. May 2;https:\/\/doi.org\/10.1093\/neuonc\/noac116, (2022).","DOI":"10.1093\/neuonc\/noac116"},{"key":"48326_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","volume":"226","author":"KM Tewey","year":"1984","unstructured":"Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D. & Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466\u2013468 (1984).","journal-title":"Science"},{"key":"48326_CR24","doi-asserted-by":"publisher","first-page":"e1637188","DOI":"10.1080\/2162402X.2019.1637188","volume":"8","author":"O Kepp","year":"2019","unstructured":"Kepp, O., Zitvogel, L. & Kroemer, G. Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade. Oncoimmunology 8, e1637188 (2019).","journal-title":"Oncoimmunology"},{"key":"48326_CR25","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691\u20131701 (2005).","journal-title":"J. Exp. Med."},{"key":"48326_CR26","doi-asserted-by":"publisher","first-page":"110138","DOI":"10.1016\/j.celrep.2021.110138","volume":"37","author":"NL Ka","year":"2021","unstructured":"Ka, N. L., Lim, G. Y., Hwang, S., Kim, S. S. & Lee, M. O. IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell Rep. 37, 110138 (2021).","journal-title":"Cell Rep."},{"key":"48326_CR27","doi-asserted-by":"publisher","unstructured":"Luthra P., et al. Topoisomerase II Inhibitors induce DNA damage-dependent interferon responses circumventing ebola virus immune evasion. mBio. 04 04;8, https:\/\/doi.org\/10.1128\/mBio.00368-17, (2017).","DOI":"10.1128\/mBio.00368-17"},{"key":"48326_CR28","doi-asserted-by":"publisher","unstructured":"Wilkinson RDA, et al. Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation. bioRxiv. https:\/\/doi.org\/10.1101\/764662, (2019).","DOI":"10.1101\/764662"},{"key":"48326_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"48326_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20100269","volume":"208","author":"Y Ma","year":"2011","unstructured":"Ma, Y. et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491\u2013503 (2011).","journal-title":"J. Exp. Med."},{"key":"48326_CR31","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","volume":"71","author":"SR Mattarollo","year":"2011","unstructured":"Mattarollo, S. R. et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809\u20134820 (2011).","journal-title":"Cancer Res."},{"key":"48326_CR32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"48326_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"48326_CR34","doi-asserted-by":"publisher","unstructured":"Portnow J., et al. Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4508, (2020).","DOI":"10.1001\/jamaoncol.2020.4508"},{"key":"48326_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1352458508098268","volume":"15","author":"HF Petereit","year":"2009","unstructured":"Petereit, H. F. & Rubbert-Roth, A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult. Scler. 15, 189\u2013192 (2009).","journal-title":"Mult. Scler."},{"key":"48326_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"HJ Stemmler","year":"2007","unstructured":"Stemmler, H. J. et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18, 23\u201328 (2007).","journal-title":"Anticancer Drugs"},{"key":"48326_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-104","volume":"7","author":"I Alagkiozidis","year":"2009","unstructured":"Alagkiozidis, I. et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J. Transl. Med. 7, 104 (2009).","journal-title":"J. Transl. Med."},{"key":"48326_CR38","doi-asserted-by":"publisher","unstructured":"Takayama T., et al. Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil. Pharmaceutics. Oct 19;12, https:\/\/doi.org\/10.3390\/pharmaceutics12100990 (2020).","DOI":"10.3390\/pharmaceutics12100990"},{"key":"48326_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0567-9","volume":"10","author":"J Yuan","year":"2018","unstructured":"Yuan, J. et al. Single-cell transcriptome analysis of lineage diversity in high-grade glioma. Genome Med. 10, 57 (2018).","journal-title":"Genome Med."},{"key":"48326_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nn.4185","volume":"19","author":"D Hambardzumyan","year":"2016","unstructured":"Hambardzumyan, D., Gutmann, D. H. & Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20\u201327 (2016).","journal-title":"Nat. Neurosci."},{"key":"48326_CR41","doi-asserted-by":"publisher","unstructured":"Arrieta V. A., et al. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms222413382 (2021).","DOI":"10.3390\/ijms222413382"},{"key":"48326_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 Expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"48326_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","volume":"75","author":"K Schroder","year":"2004","unstructured":"Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163\u2013189 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"48326_CR44","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik, A. et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286\u20134293 (2015).","journal-title":"Clin. Cancer Res."},{"key":"48326_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-018-0023-4","volume":"556","author":"AC Wendeln","year":"2018","unstructured":"Wendeln, A. C. et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature 556, 332\u2013338 (2018).","journal-title":"Nature"},{"key":"48326_CR46","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178, 835\u2013849.e21 (2019).","journal-title":"Cell"},{"key":"48326_CR47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40259-013-0070-1","volume":"27","author":"KA Lyseng-Williamson","year":"2013","unstructured":"Lyseng-Williamson, K. A., Duggan, S. T. & Keating, G. M. Pegylated liposomal doxorubicin: a guide to its use in various malignancies. BioDrugs 27, 533\u2013540 (2013).","journal-title":"BioDrugs"},{"key":"48326_CR48","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.7150\/thno.54630","volume":"11","author":"C Kim","year":"2021","unstructured":"Kim, C. et al. Closed-loop trans-skull ultrasound hyperthermia leads to improved drug delivery from thermosensitive drugs and promotes changes in vascular transport dynamics in brain tumors. Theranostics 11, 7276\u20137293 (2021).","journal-title":"Theranostics"},{"key":"48326_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jconrel.2014.05.033","volume":"187","author":"Z Kovacs","year":"2014","unstructured":"Kovacs, Z. et al. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. J. Control Release 187, 74\u201382 (2014).","journal-title":"J. Control Release"},{"key":"48326_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36340-0","volume":"9","author":"T Mainprize","year":"2019","unstructured":"Mainprize, T. et al. Blood-brain barrier opening in primary brain tumors with non-invasive mr-guided focused ultrasound: a clinical safety and feasibility study. Sci. Rep. 9, 321 (2019).","journal-title":"Sci. Rep."},{"key":"48326_CR51","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka, K. et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 4175\u20134186 (2018).","journal-title":"Clin. Cancer Res."},{"key":"48326_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2921","volume":"4","author":"B Pang","year":"2013","unstructured":"Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun. 4, 1908 (2013).","journal-title":"Nat. Commun."},{"key":"48326_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.cub.2013.03.043","volume":"23","author":"F Yang","year":"2013","unstructured":"Yang, F., Kemp, C. J. & Henikoff, S. Doxorubicin enhances nucleosome turnover around promoters. Curr. Biol. 23, 782\u2013787 (2013).","journal-title":"Curr. Biol."},{"key":"48326_CR54","doi-asserted-by":"publisher","unstructured":"Arrieta V. A., et al. ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-021-00260-2 (2021).","DOI":"10.1038\/s43018-021-00260-2"},{"key":"48326_CR55","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"48326_CR56","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","volume":"6","author":"TM Johanns","year":"2016","unstructured":"Johanns, T. M. et al. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov. 6, 1230\u20131236 (2016).","journal-title":"Cancer Discov."},{"key":"48326_CR57","doi-asserted-by":"publisher","unstructured":"Arrieta V. A., et al. ERK1\/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1\/CTLA-4 Immunotherapy: A REMARK-Guided Analysis. Clin. Cancer Res. Nov 08; https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1889 (2023).","DOI":"10.1158\/1078-0432.CCR-23-1889"},{"key":"48326_CR58","doi-asserted-by":"publisher","unstructured":"Arrieta V. A., et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. Jan 17 133, https:\/\/doi.org\/10.1172\/JCI163447, (2023).","DOI":"10.1172\/JCI163447"},{"key":"48326_CR59","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"48326_CR60","doi-asserted-by":"publisher","unstructured":"Rodig S. J., et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 07 18 10 https:\/\/doi.org\/10.1126\/scitranslmed.aar3342 (2018).","DOI":"10.1126\/scitranslmed.aar3342"},{"key":"48326_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10582","volume":"7","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat. Commun. 7, 10582 (2016).","journal-title":"Nat. Commun."},{"key":"48326_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3","volume":"9","author":"KG Paulson","year":"2018","unstructured":"Paulson, K. G. et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat. Commun. 9, 3868 (2018).","journal-title":"Nat. Commun."},{"key":"48326_CR63","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1 + CD38 hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"48326_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","volume":"159","author":"EK Lee","year":"2020","unstructured":"Lee, E. K. et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol. Oncol. 159, 72\u201378 (2020).","journal-title":"Gynecol. Oncol."},{"key":"48326_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02421-w","volume":"18","author":"JA Kyte","year":"2020","unstructured":"Kyte, J. A. et al. ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. J. Transl. Med. 18, 269 (2020).","journal-title":"J. Transl. Med."},{"key":"48326_CR66","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"48326_CR67","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","volume":"6","author":"SM Pollack","year":"2020","unstructured":"Pollack, S. M. et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial. JAMA Oncol. 6, 1778\u20131782 (2020).","journal-title":"JAMA Oncol."},{"key":"48326_CR68","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA. 99, 12293\u201312297 (2002).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"48326_CR69","doi-asserted-by":"crossref","unstructured":"Arrieta, V. A. et al. Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma? J. Neurosurg. 132, 1667\u20131672 (2019).","DOI":"10.3171\/2019.9.JNS192523"},{"key":"48326_CR70","doi-asserted-by":"publisher","first-page":"eabe6201","DOI":"10.1126\/scitranslmed.abe6201","volume":"13","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci. Transl. Med. 13, eabe6201 (2021).","journal-title":"Sci. Transl. Med."},{"key":"48326_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20469-6","volume":"12","author":"M Gromeier","year":"2021","unstructured":"Gromeier, M. et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat. Commun. 12, 352 (2021).","journal-title":"Nat. Commun."},{"key":"48326_CR72","doi-asserted-by":"publisher","first-page":"12550","DOI":"10.1073\/pnas.1405839111","volume":"111","author":"BJ Gill","year":"2014","unstructured":"Gill, B. J. et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc. Natl Acad. Sci. Usa. 111, 12550\u201312555 (2014).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"48326_CR73","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3174\/ajnr.A5112","volume":"38","author":"PD Chang","year":"2017","unstructured":"Chang, P. D. et al. A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am. J. Neuroradiol. 38, 890\u2013898 (2017).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"48326_CR74","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nbt.2594","volume":"31","author":"AD Amir el-","year":"2013","unstructured":"Amir el-, A. D. et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31, 545\u2013552 (2013).","journal-title":"Nat. Biotechnol."},{"key":"48326_CR75","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/2326-6066.CIR-19-0240","volume":"7","author":"C Lee-Chang","year":"2019","unstructured":"Lee-Chang, C. et al. Myeloid-derived suppressive cells promote b cell-mediated immunosuppression via transfer of pd-l1 in glioblastoma. Cancer Immunol. Res. 7, 1928\u20131943 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"48326_CR76","doi-asserted-by":"publisher","first-page":"e1005112","DOI":"10.1371\/journal.pcbi.1005112","volume":"12","author":"H Chen","year":"2016","unstructured":"Chen, H. et al. Cytofkit: a bioconductor package for an integrated mass cytometry data analysis pipeline. PLoS Comput Biol. 12, e1005112 (2016).","journal-title":"PLoS Comput Biol."},{"key":"48326_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"48326_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"DM Bates","year":"2015","unstructured":"Bates, D. M., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1\u201348 (2015).","journal-title":"J. Stat. Softw."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48326-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T06:04:46Z","timestamp":1717653886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48326"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-48326-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. Sonabend and R. Stupp have received in-kind and or funding support for research from Agenus, BMS, and Carthera. A.M. Sonabend, V.A. Arrieta, KS. Kim, C. Amidei, and R. Stupp are co-authors of an IP filed by Northwestern University related to the content of this manuscript (\u201cCANCER IMMUNOTHERAPIES\u201d No. PCT\/US2023\/034299). A.M. Sonabend has served as consultant for Carthera and EnClear Therapies. R. Stupp has acted or is acting as a scientific advisor or has served on advisory boards for the following companies: Alpheus Medical, AstraZeneca, Boston Scientific, Carthera, Celularity, GT Medical, Insightec, Lockwood (BlackDiamond), Northwest Biotherapeutics, Novocure, Inc., Syneos Health (Boston Biomedical), TriAct Therapeutics, Varian Medical Systems. C. Desseaux, G. Bouchoux, and M. Canney are employees and hold an ownership interest in Carthera. M. Canney, G. Bouchoux, and A. Carpentier have patents related to the ultrasound technology described herein. R. Stupp is an advisory member and consultant for Carthera. A. Carpentier is a consultant for Carthera. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4698"}}